Greenwich LifeSciences

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

At Greenwich LifeSciences, we are dedicated to developing effective immunotherapies to simplify and improve the care of cancer patients. We are passionate about finding ways to improve cancer outcomes and expanding access to therapies for patients in need.

Our vision is to be the leading biopharmaceutical company dedicated to the delivery of safe and effective immunotherapies to cancer patients. We are committed to providing the highest quality of care and establishing our products as the gold standard for cancer treatments.

Greenwhich LifeSciences has received many awards and recognition, including the 2019 Innovative Company of the Year by the American Association for Cancer Research and the 2019 Top 10 Company in Early Stage Cancer Clinical Trials by BioPharma. In addition, the company was named a Technology Pioneer by the World Economic Forum in 2018.